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Long term follow up of HIV-infected patients with
tuberculosis treated with 6-month intermittent
short course chemotherapy
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ABSTRACT
Background. Tuberculosis occurs in 60%–70% of HIV-
positive persons in India. The outcome of HIV-positive patients
treated with 6-month intermittent short course antituberculosis
regimens in India is not well described.
Methods. This was a prospective observational feasibility
study of 71 patients with HIV and tuberculosis who were treated
with category I regimen of the Revised National Tuberculosis
Control Programme (ethambutol, isoniazid, rifampicin and
pyrazinamide thrice weekly for the initial 2 months followed by
rifampicin and isoniazid thrice weekly for the next 4 months).
Sputum was examined by smear and culture for Mycobacterium
tuberculosis every month up to 24 months. Chest X-ray, CD4 cell
count and viral load were done prior to and at the end of
treatment. None of the patients received antiretroviral therapy.
Results. We present here the treatment response of patients
with sputum culture-positive pulmonary tuberculosis to category
I regimen. By efficacy analysis, among 43 patients treated with
category I regimen, sputum smear conversion was observed in
79% and culture conversion in 82% at the second month. A
favourable response was seen in 72% of patients. The mean (SD)
CD4% fell from 12.6 (5.9) to 8.9 (4.9) (p<0.001) with no
significant change in mean (SD) CD4 cell count (169 [126] to
174 [158]; ns) at the end of treatment. Viral load change from
1.8x105 at baseline to 1.3x105 at the end of treatment was not
statistically significant. Thirty-one patients, who completed the
full course of treatment, were declared cured and were followed
up for 24 months. Twelve had recurrent tuberculosis (39%); 16
of 43 (37%) patients had died by the end of 24 months, two-
thirds due to causes other than tuberculosis.
Conclusion. Though the early bacteriological response to
intermittent short course antituberculosis regimen was satisfactory,
the overall outcome was adversely affected by the high mortality
(during and after completion of treatment) and recurrence rate
among HIV-infected patients with tuberculosis. Immune status
deteriorated in spite of antituberculosis treatment, highlighting
the need for antiretroviral treatment in addition to antituberculosis
treatment to improve the long term outcome. The results of this
pilot study need to be confirmed by larger studies.
Natl Med J India 2008;21:3–8
INTRODUCTION
The human immunodeficiency virus (HIV) epidemic has had a
major impact on the worldwide incidence of tuberculosis (TB). It
is estimated that nearly 2 billion people are infected with
Mycobacterium tuberculosis, 40 million are HIV-infected and
over 12 million have dual infection with M. tuberculosis and
HIV.1,2 A prospective study at the Tuberculosis Research Centre
(TRC), Chennai found a TB incidence rate of 6.9/100 person-
years (95% CI: 4.1–9.6) in patients infected with HIV without a
significant difference between initially tuberculin-positive and
-negative subjects.3 The growing number of patients with HIV-
related TB is placing increasing pressure on the already heavily
burdened TB control programme and resources.
Intermittent short course regimens have been proven to be
highly effective and well tolerated in HIV-uninfected patients with
TB.4 However, reports characterizing the outcome of intermittent
short course chemotherapy among patients with HIV-associated
TB are few. Though some studies5–7 have shown a good short term
response to standard short course antitubercular therapy (ATT),
considerable uncertainty remains regarding some aspects such as
effectiveness under programme conditions, recurrence of TB and
mortality. It is important for the Indian TB control programme to
know whether or not patients with TB co-infected with HIV can be
treated with the standard regimens used in the Revised National
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Tuberculosis Control Programme (RNTCP).8 We report the results
of a feasibility study in a group of patients with HIV and TB who
did not have access to antiretroviral therapy (ART) and were treated
with standard intermittent short course therapy used in the RNTCP.
Patients were followed for 24 months after completing ATT.
METHODS
This was a prospective, observational, feasibility study. Between
July 1999 and June 2000, HIV-infected individuals referred to
TRC and those admitted in Government Hospital of Thoracic
Medicine (GHTM), Tambaram, Chennai were assessed for their
eligibility to participate in the study. Patients were enrolled if they
were ambulatory and at least 15 years of age, had at least one
sputum smear-positive for M. tuberculosis or had radiological or
histopathological evidence of extrapulmonary TB. Almost 50%
of our study population were from outside the city but were
willing to attend the clinic as required. Pregnant and moribund
patients were excluded from enrolment to the study. A history of
patients having received ATT was elicited and patients were
categorized and treated as per the RNTCP guidelines.
A standard questionnaire containing demographic, medical
and behavioural characteristics was administered and all patients
underwent a physical examination. Baseline investigations
included a chest X-ray and examination of two overnight and
one spot sputum specimens by direct smear microscopy and
culture for mycobacteria. Cultures were subjected to species
identification and those positive for M. tuberculosis were tested
for sensitivity to isoniazid (H), ethambutol (E), streptomycin (S)
and rifampicin (R).9,10 Evaluation of baseline hepatic and renal
functions, and serological testing for HIV were done for all
patients. HIV screening was done using the Tridot rapid test (J.
Mitra, India) and positive tests were confirmed by Comb Aids
rapid test (Span Diagnosis, Surat, India) and also by enzyme-
linked immunosorbent assay (Labsystems, UK). National
guidelines and policy concerning HIV testing and related issues
(informed consent, confidentiality, pre- and post-test counselling)
were adhered to. Haematological and immunological parameters
were measured. CD4%, CD8% and CD4, CD8 cell counts,
CD4:CD8 ratio were determined using flow cytometry (Simultest-
IMK Lymphocyte kit and a Becton Dickinson FAC scan) and
viral load was measured using Cobas Amplicor automated viral
load monitor (Roche amplicor, V3.1).
All eligible patients (i.e. patients >15 years of age, no history
of TB or receiving ATT with current evidence of pulmonary or
extrapulmonary TB) received the standard short course ATT
regimen category I, as recommended by RNTCP.8
Category I consists of ethambutol, isoniazid, rifampicin and
pyrazinamide thrice weekly for the initial 2 months (intensive
phase; 2EHRZ3), followed by rifampicin and isoniazid thrice
weekly for the next 4 months (continuation phase; 4RH3).
The drug dosages were: isoniazid 600 mg, ethambutol 1200 mg,
pyrazinamide 1.5 g, streptomycin 0.75 g and rifampicin 450 mg for
patients weighing <60 kg. For those weighing >60 kg the dose of
rifampicin was increased to 600 mg. Tablet pyridoxine 10 mg was
given with each dose of ATT. Fixed drug combinations were not
used. The study protocol was approved by the scientific advisory
and the ethics committees of the TRC, Chennai and written informed
consent was obtained from the patients.
Monitoring during treatment and follow up
All patients received treatment under supervision during the
intensive phase and were supplied drugs once weekly during the
continuation phase. Community DOT (directly observed treatment)
providers were arranged for those patients unable to attend the
clinic as required during the continuation phase. Field investigators
from the hospital visited these community DOT providers every
month to supervise and educate them on how to dispense ATT
drugs, how to maintain the DOT notebook, etc. When these
patients attended the centre for monthly examination, besides
doing a thorough clinical examination, regularity of their drug
intake was checked by re-questioning them, performing a urine
examination for acetyl-INH and by checking their DOT notebooks,
which should have been duly dated and signed by their DOT
providers. If a patient had missed an appointment, a health visitor
made a home visit the next day, if the patient lived in the city.
Otherwise a letter was posted to him or to his DOT provider.
Subsequently, a social worker and a medical officer made home
visits, if necessary. These visits were continued until the patient
was either retrieved or ‘lost’; loss being defined as continuously
defaulting for more than 1 month. Any complaint suggestive of an
adverse reaction volunteered by a patient during the treatment
period was recorded and a clinician elicited further details. If the
complaints were related to the ATT drugs administered, suitable
action was taken wherever necessary.
All patients were monitored at monthly intervals for 2 years
following completion of treatment. Follow up examinations
included clinical assessment, regularity of drug intake and
monitoring of adverse drug reactions. Three sputum specimens
during treatment and two specimens during follow up were
examined at monthly intervals up to 2 years by microscopy and
culture. If a culture grew M. tuberculosis it was tested for
sensitivity to first-line drugs to monitor the emergence of drug
resistance. Chest X-ray was done at the second month and at the
end of treatment while blood examination for liver functions and
immunological parameters was done at the end of ATT (6 months)
and at any other time considered necessary (clinical deterioration).
During follow up patients who were late for their scheduled
appointment by 15 days were contacted at their homes, and
all attempts made to motivate them to attend the clinic at the
earliest. Patients in this cohort received co-trimoxazole (1 double
strength tablet daily) along with medications for intercurrent
illnesses and other opportunistic infections. After completing
treatment if the sputum smears/culture became positive at any
time they had a chest X-ray, were re-evaluated clinically and
managed appropriately. None of the patients in this study received
ART because ART was not available in government hospitals
during this period and since all our patients were from the lower
socioeconomic stratum none of them could afford ART.
Outcome measures
A patient was considered to have had
1. a favourable response, if all the 6 cultures were negative
during the last 2 months of treatment.
2. an unfavourable response, if one or more cultures were
positive in the last 2 months of treatment, sputum smear
positivity at 5 months or more after starting treatment (treatment
failure), death due to TB, a change of treatment for clinical/
radiographic deterioration or for persistent culture positivity.
3. a recurrence of TB, if one or more cultures became positive or
there was clinical/bacteriological deterioration during follow
up among patients who had a favourable response at the end
of treatment.
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5to 1 157 200 copies/ml). Regularity of drug intake was monitored
by questioning the patient, urine examination for acetyl-INH and
through visits to monitor the community DOT providers as
described earlier. Only patients with more than 80% of drug intake
were considered for the efficacy analysis.
Of the 71 patients, 28 patients were excluded from the efficacy
analysis due to various reasons: initial culture negativity (n=16),
<80% of drug intake (n=9), or death within 1 month of starting
treatment (n=3). Among the 43 patients available for efficacy
analysis, favourable response, defined as culture negativity at the
end of treatment with clinical and radiological improvement, was
Statistical analysis
Statistical analysis was done using the statistical package for
social sciences (SPSS version 13). Descriptive analysis was done
for demographic details and the difference between variables at
baseline and at end of therapy was assessed by paired t-test. An
efficacy analysis was done for patients who had received more
than 80% of the prescribed chemotherapy. For all tests, p<0.05
was considered statistically significant.
RESULTS
Of the 71 patients given the category I regimen, the majority were
men (83%) with ages ranging from 18 to 55 years with a median
age of 33 years (mean [SD] age: 33.5 [7.2] years) and weight
ranging from 28 kg to 73 kg with a median weight of 40 kg (mean
weight: 41.4 [7.6] kg). At the time of enrolment, most patients had
a combination of two or more symptoms such as cough or fever
and weight loss. Extensive parenchymal opacity was the
commonest chest X-ray abnormality followed by miliary mottling;
24 patients had more than 1 radiological lesion; 65% of patients
had positive sputum smears, while culture positivity was seen in
73% (n=55) of patients initially. Among patients who had a drug
sensitivity pattern available (n=52), 43 (83%) had organisms that
were sensitive to all the first-line TB drugs, 15% were resistant to
isoniazid and 4% had MDR TB. The mean CD4% was 12.5%
(range 2%–29%), mean CD4 count 169 (126) cells/cmm while the
median viral load was 188 000 (interquartile range (IQR): 41 100
TABLE I. Laboratory parameters (mean [SD]) at baseline and end
of treatment (paired)
Parameter n Baseline End of p value
treatment
Weight (kg) 55 41.4 (7.6) 48.1 (9.3) <0.001
Haemoglobin (g/dl) 55 11.1 (2.7) 11.7 (1.8) 0.005
Total lymphocyte 33 1305 (644) 1902 (1160) <0.05
count (cmm)
CD4% 37 12.6 (5.9) 8.9 (4.9)  <0.001
CD4 cell 34 169 (126) 174 (158) ns
counts (mm3)
Median viral load 14 188 000 132 000 ns
(IQR) (copies/ml) (41 100–1 157 200) (16 400–614 000)
IQR interquartile range
FIG 1. Schematic presentation of study population and outcome
Total patients assessed
n=332
Patients enrolled to study
n=100
Category III = 10 patients Category I = 71 patients Category II = 19 patients
Early death <1 month: 3
Culture negative: 16
Inadequate treatment: 9
Category I patients eligible for
efficacy analysis (n=43)
At the end of treatment
Favourable response Unfavourable response
n=31 (72%) n=12 (28%)
After 24 months
follow up
Death: 3
Failure: 9
Disease quiescent Death n= 7 Relapse n=12 (39%)n=12 (39%) (6 died after relapse)
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various time points which included early death within 1 month
(n=3), death during treatment (n=3), death during follow up (n=7)
and death after recurrence (n=6). Considering the 43 patients
eligible for efficacy analysis, 16 patients (37%) died by the end of
2 years of follow up, 6 of them being after recurrence of TB.
DISCUSSION
In this prospective observational study, we have shown that
among HIV-infected individuals with TB who were treated with
category I regimen and were regular with treatment, the initial
bacteriological response to ATT was good. Overall, however,
only 72% of patients (31/43) had a favourable response while 28%
(12/43) had an unfavourable response at the end of treatment
which included death, treatment change and culture positivity.
Both cure and death rates compare unfavourably with rates
reported for HIV-negative TB patients treated under the RNTCP.10
Many reports5–7,11 have shown that 6- and 9-month courses of
ATT regimens containing isoniazid and rifampicin are highly
effective in TB patients with HIV disease, with high cure but
variable recurrence rates. Two studies6,7 describing the results of
6-month therapy for TB in HIV-positive patients have shown cure
rates, at the end of treatment, of 59% and 81%, respectively. Our
results showed that patients with HIV infection and culture
confirmed pulmonary TB who take regular treatment have a
favourable response of 72% when treated with a 6-month
intermittent regimen. This cure rate is less than the 85% reported
in the RNTCP from most parts of India. This may be due to the
selected group of patients with advanced stage of HIV disease in
our study. The possible reasons for treatment failure could be
malabsorption of drugs exacerbated by diarrhoea and other
associated opportunistic infections. We have earlier demonstrated
that patients with advanced HIV disease have evidence of
malabsorption and low blood levels of ATT drugs.12
A survey to determine the proportion of initial and acquired
drug resistance among patients with pulmonary TB in Tamil Nadu
showed 81% of organisms susceptible to all first-line drugs,
isoniazid resistance in 15.4%, rifampicin resistance in 4.4% and
resistance to isoniazid and rifampicin in 3.4% of previously
untreated cases.13 Recent reports14,15 on the prevalence of drug
resistance among HIV-infected TB patients from Chennai and
Pune have shown that it was similar to HIV-negative patients from
the same geographical area. This study confirms the finding that
the majority of HIV-infected TB patients have drug-susceptible
organisms and that MDR TB is still fairly low in this population.
Recurrence of TB in HIV-infected patients is a serious problem
and may be due to re-activation or re-infection with a new strain
of M. tuberculosis. Recent observations16 in countries endemic
for HIV/TB suggest that recurrence rates following TB treatment
may be unacceptably high in HIV-infected individuals, even
when the DOT strategy recommended by WHO17 is followed.
Studies done in various parts of the world have reported a
recurrence rate of TB in HIV-infected persons ranging from 4.6%
to 9% in non-endemic areas6,18,19 and 50% to 62% in TB-endemic
areas.16,20 In our series, recurrence of TB was observed in 39% of
category I patients followed up to 24 months. This high rate could
be due to the advanced stage of HIV disease in this group with
two-thirds of patients having a CD4 cell count <200 cells/cmm at
presentation, as recurrence of TB is more likely to occur among
severely immunocompromised patients.21 Another reason could
be exposure to TB in the hospital environment as many patients
were admitted for a long duration and were exposed to other
sputum-positive TB patients in the wards thus increasing the
seen in 31 patients (72%). At the end of treatment, 12 patients
(28%) had unfavourable response in the form of death (n=3) or
treatment failure (n=9) (Fig. 1). Sputum smear conversion among
the initial smear-positive patients at second month was 79% and
culture conversion was 82%. Table I shows a comparison of
various parameters at baseline and at the end of treatment among
patients who had paired data available. There was a significant
improvement in weight, haemoglobin and absolute lymphocyte
count at the end of ATT, while the CD4% declined significantly.
Adverse drug reactions attributable to ATT (rifampicin)
occurred in one patient in our study. The patient developed acute
hepatitis, elevated liver enzymes more than 3 times the upper limit
of normal and bleeding diathesis about 25 days after starting ATT.
In view of the above symptoms the patient was changed to a
regimen that did not include rifampicin. She improved subsequently
and completed her course of chemotherapy. Gastrointestinal
reactions such as nausea, vomiting and epigastric disturbance
were seen in a few patients that were managed symptomatically
with reassurance and antacids. None of them required any
modification in their drug dosages or regimen.
Long term follow up
At the end of 24 months of follow up, among patients who had a
favourable response to category I regimen (n=31), 12 patients had
quiescent disease, 7 had died and 12 had recurrence of TB.
Of the 12 patients with recurrent TB there were 11 men and
1 woman (age range 21–38 years). The majority of recurrences
(7 of 12) occurred within the first 6 months of completion of
treatment. Of these 12 patients, 7 had a high bacteriological load
of 2+ or more in their initial sputum culture, 9 patients had
organisms susceptible to all first-line ATT drugs at the beginning
and 10 of them were severely immunocompromised, even at
baseline, with CD4 cell counts <200 cells/cmm (Table II). Patients
who developed recurrence were significantly older than those
who did not. None of the other variables were significantly
different even though there was a trend towards lower initial CD4
counts and weight, and higher smear grading in the recurrence
group.
Of the 71 patients, excluding the initial culture negatives
(n=16), 55 patients were considered for death analysis. Nineteen
(35%) of them had died by the end of 24 months of follow up at
TABLE II. Comparison of pre-treatment characteristics of HIV-
infected TB patients who developed a recurrence of TB versus
those who remained quiescent
Characteristic Recurrence (n=12) Quiescent (n=12)
Mean (SD) age (in years) 36.7 (5.4) 30 (5.1)*
Sex ratio (M:F) 11:1 9: 3
Mean (SD) weight (in kg) 41.2 (4.6) 45.0 (7.9)
Mean (SD) CD4% 11.8 (6.5) 16.4 (8.4)
Mean (SD) CD4 cell count 156 (162) 272 (251)
Pre-treatment sensitivity
Pansensitivity 9 11
MDR TB 1 –
Not available 2 1
Sputum smear grading
0 to 1+ 7 11
2+ to 3+ 5 1
Sputum culture grading
0 to 1+ 5 6
2+ to 3+ 7 6
* p value <0.001 MDR TB multidrug resistant tuberculosis
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7chances of re-infection with different strains of M. tuberculosis.
This raises the issue of implementing proper infection control
procedures in hospital wards and segregation of infectious
patients to prevent nosocomial spread of TB. We have earlier
described TB recurrence due to re-infection with a new strain
of M. tuberculosis in a patient with advanced HIV disease.22
Further studies using molecular techniques such as restriction
fragment length polymorphism (RFLP) are required to find out
the proportion of recurrences due to re-infection in India. Further,
treatment was not fully supervised in the continuation phase in our
study as many patients were from remote places and we had to
depend on community DOT providers for drug administration and
concealed irregularity is a possibility. A recent study from our
centre showed that irregular treatment, smoking and pre-treatment
drug resistance were strong risk factors for recurrence.23 In this
study of HIV-infected TB patients, those who developed recurrent
TB had poorer immune status, lower body weight and a higher
sputum smear grading initially, though the differences were not
statistically significant. One of them had MDR TB to begin with
and another 6 developed rifampicin resistance at the time of
recurrence. The development of rifampicin resistance is of concern
and could imply three things. First, if the patients were irregular
when intermittent chemotherapy was not supervised, this could
have led to drug resistance. Second, malabsorption of drugs could
have led to development of rifampicin resistance because of
subtherapeutic blood levels of one or more ATT drugs; the third
possibility is that re-infection occurred with a drug-resistant strain
of M. tuberculosis
Several other aspects of our results are pertinent to the
management of HIV-related TB. The clinical features of our
patients have been described in detail earlier; the most common
presenting symptoms were cough and weight loss followed by
fever.24 Of the 71 HIV-positive cases treated with category I
regimen, 65% were smear-positive for acid-fast bacilli. This
indicates that smear microscopy done diligently could be a sensitive
diagnostic tool even in the presence of HIV infection. This is
contrary to the general belief that sputum smears are more likely
to be negative in HIV-infected individuals.4
The association of TB and high viral loads portends a more
rapid course of HIV disease, even in patients in whom TB
is treated and cured.25 Patients in our study had high viral
loads, which did not decrease significantly after treatment.
While there was no significant change in CD4 cell counts, there
was a significant decrease in CD4% indicating progressive
immunosuppression. CD4 absolute count is influenced by the
total lymphocyte count, which was found to increase significantly
after treatment of TB. The CD4% is a more reliable and independent
marker of disease progression and response to treatment in such
situations.
A few previous studies have reported the 1-year mortality for
HIV-infected TB patients to be 20%–25%.26,27 Studies have also
shown that early death in cases of HIV-related TB was more likely
due to TB, whereas late death was due to other HIV-related
complications.28,29 Due to the non-availability of free ART during
the course of our study and since most of our patients were from
the lower socioeconomic group they did not have access to ART.
Sixteen of our 43 patients (37%) died by the end of 2 years, two-
thirds due to causes other than TB. Of the 16 deaths, 6 patients died
after recurrence of TB. Thus, the long term prognosis for patients
with HIV and TB is poor, particularly when there is limited access
to ART.
The results of our study must be interpreted with caution and
cannot be generalized. The number of patients studied was
relatively small and treatment was not supervised completely; in
many instances community DOT providers were used. However,
the study provides valuable preliminary data, which can be used
to plan future research studies. Larger studies are required to
determine if there is a CD4 lymphocyte level below which the risk
of recurrence of TB is increased, which could identify patients for
whom the duration of ATT should be extended. A randomized
clinical trial is under way at the TRC comparing a 9-month
regimen with the standard RNTCP 6-month regimen in the
treatment of HIV-associated TB. The mortality reported here
underscores the need for access to ART for HIV-infected
individuals and those who present with TB would form a good
target group for ART.
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Surveillance for risk factors of cardiovascular disease among
an industrial population in southern India
V. MOHAN,  M. DEEPA,  S. FAROOQ,  D. PRABHAKARAN,  K. S. REDDY
ABSTRACT
Background. We assessed (i) the risk of cardiovascular
disease in an industrial population in Chennai, southern India and
(ii) whether the status of treatment and control of diabetes and
hypertension would be different in an industrial population,
which is provided free healthcare, compared with the general
population of Chennai.
Methods. Subjects residing in the residential areas of 2
industries (Indian Airlines and Integral Coach Factory) in Chennai
in southern India were recruited. The subjects were employees
(n=440) selected by an age- and sex-stratified random sampling
method, and their family members (n=727) in the age group
of 20–69 years; a total of 1167 subjects. Fasting plasma glucose,
lipid estimations and anthropometric measurements were done
in all the subjects. Information on demographic and lifestyle
determinants was obtained using a questionnaire. Diabetes was
diagnosed using the American Diabetes Association criteria
and metabolic syndrome was defined by the Adult Treatment
Panel III criteria with modified waist definition for Asian Indians.
Results. Age-adjusted prevalence of major risk factors for
cardiovascular disease using the 2001 Census of India were as
follows: diabetes 11.9%; hypertension 25.4%; dyslipidaemia
40.2%; hypertriglyceridaemia 28.3%; overweight (body mass
index ≥23 kg/m2) 60.2%; and metabolic syndrome 34.1%.
Use of tobacco in any form was present in 22.9% of men and
0.5% of women; 79% of the subjects followed a sedentary
lifestyle. Among subjects receiving medication, 42.1% of subjects
with diabetes and 55.3% of subjects with hypertension had their
disease under adequate control. A comparison of these results
with the general population of Chennai showed that the industrial
population had a higher prevalence of cardiovascular risk factors
in spite of having better access to healthcare facilities.
Conclusions. The prevalence of cardiovascular disease was
high in this industrial population of Chennai. Although the overall
treatment and control of diabetes and hypertension was better
than that in the general population, it was still inadequate and this
emphasizes the need for greater awareness about non-
communicable diseases.
Natl Med J India 2008;21:8–13
INTRODUCTION
Cardiovascular disease (CVD) is predicted to be the most common
cause of death globally, including in India, by 2020.1 The prevalence
of CVD and its risk factors are high in migrant people of Asian
Indian origin compared with the host population.2,3 The growing
burden of CVD4 is due to the increasing prevalence of cardiovascular
risk factors such as diabetes, hypertension, dyslipidaemia, overweight
or obesity, physical inactivity and use of tobacco. It is known that
CVD occurs at least a decade earlier in Asian Indians compared
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